Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0000905718-18-000979
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-12-19 16:18:08
Reporting Period:
2018-12-17
Accepted Time:
2018-12-19 16:18:08
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1042074 Cymabay Therapeutics Inc. CBAY Pharmaceutical Preparations (2834) 943103561
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1252524 Von Kurt Emster C/o Cymabay Therapeutics, Inc.
7999 Gateway Blvd, Suite 130
Newark CA 94560
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2018-12-17 88,889 $8.17 184,528 No 4 S Indirect See footnotes
Common Stock Disposition 2018-12-18 53,492 $7.43 131,036 No 4 S Indirect See footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See footnotes
No 4 S Indirect See footnotes
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 18,316 Indirect By the Konrad Hans von Emster III and Elizabeth F. von Emster Revocable Trust dated January 18, 2005
Common Stock 90,000 Direct
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.03 to $8.51 per share, inclusive.
  2. The Reporting Person undertakes to provide to Cymabay Therapeutics, Inc. ("Issuer") any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.
  3. Shares are held by ABV VI. Abingworth LLP is the investment manager of ABV VI and has been delegated with all investment and dispositive power over the securities held by ABV VI. Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VI.
  4. From time to time, the investment committee may delegate investment and voting authority over certain securities held by the Abingworth Funds to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any.
  5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.24 to $8.10 per share, inclusive.